Onc.AI Introduces New AI Model to Improve Survival Assessment in NSCLC Patients | Generative ai chatgpt | Best generative ai certification microsoft | What is generative ai vs ai | Turtles AI

Onc.AI presented the Serial CTRS AI model at AACR 2025, which improves survival prediction in patients with advanced NSCLC compared to traditional methods. The model has received Breakthrough Device Designation from the FDA.

Key Points:

• AACR 2025 Presentation: Onc.AI announced results from the Serial CTRS model at the American Association for Cancer Research (AACR) 2025 Annual Meeting, showing improvements in survival prediction in patients with advanced NSCLC.
• Collaboration with GSK: The study evaluated the Serial CTRS model in Cohort E of GSK’s Phase 1 GARNET clinical trial, involving patients treated with dostarlimab, an anti-PD-1 checkpoint inhibitor.
• FDA Designation: The Serial CTRS model has received Breakthrough Device Designation from the FDA, recognizing its potential to improve outcomes for patients with NSCLC.
• Improvement over Traditional Methods: Model demonstrated superior ability to predict overall survival against RECIST 1.1 and tumor volume changes using routine CT imaging without the need for manual annotations.

Onc.AI announced the presentation of its AI model, Serial CT Response Score (Serial CTRS), at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The model was evaluated in Cohort E of GSK’s Phase 1 GARNET clinical trial, involving patients with advanced non-small cell lung cancer (NSCLC) treated with dostarlimab, an anti-PD-1 checkpoint inhibitor. Results showed that Serial CTRS, using routine CT imaging without the need for manual annotations, improved prediction of overall survival against RECIST 1.1 and tumor volume changes. Specifically, the model demonstrated superior ability to distinguish patients with intermediate probabilities from those with high probabilities of 12-month survival. This improved predictive performance supports Onc.AI’s commitment to establishing Serial CTRS as a new standard for AI-based automated imaging endpoints in early assessment of treatment response. The model has received Breakthrough Device Designation from the FDA, recognizing its potential to improve the prognosis of patients with NSCLC.

Additionally, Onc.AI collaborated with Flatiron Health, using high-quality, real-world data to develop and validate the model. This collaboration has helped strengthen the accuracy and reliability of the Serial CTRS model, making it a promising tool for improving the clinical management of cancer patients.

The Serial CTRS model represents a step forward in using AI to improve the prognosis and management of patients with advanced NSCLC, providing oncologists with a more precise tool to assess treatment response and make informed treatment decisions.